Vallergan

Quick links to important sections

Vallergan

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vallergan

Vallergan is a specialized, prescription-only medication whose active ingredient is Alimemazine, a synthetic compound known also by the International Nonproprietary Name (INN) Trimeprazine. As a prominent phenothiazine derivative, Alimemazine is chemically recognized for its core tricyclic structure, distinguishing it from newer antihistamines that lack this architecture. This established chemical class is clinically recognized for its notable psychoactive effects, supporting its dual function.


Quick Facts

Property Description
Active ingredient Alimemazine (Trimeprazine)
Form Tablets, Oral solution (Syrup)
Pharmacological class First-generation Antihistamine, Sedative
Common use Relief of pruritus (itching) and associated restlessness
Origin Synthetic, Phenothiazine derivative

The Core Identity and Classification

Vallergan is supplied as a single ingredient product, typically as Alimemazine tartrate, relying solely on the defined pharmacological properties of the active substance. The product is available for the oral route of administration, commonly prepared as tablets and as an oral solution or syrup. The liquid formulation is a distinctive feature often preferred for pediatric use or for individuals who experience difficulty swallowing.

Vallergan belongs to the first-generation antihistamine class, acting as a non-selective H1-receptor antagonist. This classification implies that the drug effectively achieves histamine blockade throughout the body. Unlike the non-sedating second-generation compounds, Alimemazine is distinguished by its strong Central Nervous System (CNS) depression capabilities, a property often leveraged therapeutically.

General Purpose and Mechanism

The general purpose of Vallergan integrates its anti-allergic mechanism with its strong central effects. The histamine blockade provides essential relief from acute and severe itching (pruritus), while the accompanying sedative and anxiolytic properties manage the related emotional and physical discomfort. For example, Vallergan is frequently used in scenarios where severe skin irritation leads to restlessness and prevents sleep, as its dual action addresses both the physical itch and the secondary insomnia.

What side effects are possible with Vallergan?

Possible Side Effects and Safety Information

The safety profile of Vallergan (trimeprazine) is defined by its properties as a first-generation phenothiazine antihistamine, primarily causing central nervous system (CNS) and anticholinergic effects.

Adverse Reactions

Adverse reactions commonly involve the Nervous System (e.g., drowsiness, dizziness, headache, agitation, insomnia) and Gastrointestinal System (e.g., dry mouth, constipation). Due to its known sedative properties, somnolence is a frequent side effect.

Serious or Clinically Significant Adverse Reactions are rare but include convulsions/seizures, agranulocytosis (a severe lack of white blood cells), severe hypersensitivity reactions (e.g., swelling of the face, difficulty breathing), and cardiovascular effects (e.g., unusual or fast heartbeats, syncope due to postural hypotension). Altered mental status, hallucinations, and loss of consciousness have also been documented, particularly in overdose.

Safety Restrictions and Population-Specific Considerations

Contraindications include a history of severe allergic reaction to trimeprazine or other phenothiazines, closed-angle glaucoma, prostate problems causing difficulty passing urine, severe liver or kidney disease, and blood disorders like agranulocytosis.

Caution is required in patients with epilepsy, heart disease, high blood pressure, thyroid problems, and chronic constipation. The medication is not recommended for use during pregnancy or breastfeeding, as the active substance passes into breast milk. Use in children under 2 years of age is contraindicated due to the risk of marked sedation and respiratory depression. Elderly patients are particularly susceptible to CNS side effects and postural hypotension, and caution is needed in extreme temperatures due to the risk of hyper- or hypothermia. Patients should avoid exposure to direct sunlight during treatment.

Overdose and Emergency Response

Overdose and when to seek help

Official Overdose Manifestations and Severe Outcomes

Overdose of Vallergan (Alimemazine) is formally documented to present with signs of severe Central Nervous System (CNS) depression, progressing from drowsiness to somnolence, and potentially to deep unconsciousness or coma. Regulatory sources also note paradoxical CNS excitation, specifically including convulsions, which is a particular concern in children. Other documented signs include severe extra-pyramidal dyskinesias and signs of autonomic instability.

The official profile highlights serious cardiovascular instability, listing hypotension, tachycardia, and severe ECG changes. These complications include QT interval prolongation and the risk of life-threatening ventricular arrhythmias, Torsade de Pointes, and cardiac arrest. Respiratory depression and circulatory collapse are cited as critical, documented outcomes.

Emergency Actions and Required Medical Intervention

Immediate medical attention is mandated for any suspected overdose due to the risk of life-threatening events. The official regulatory guidance states that symptomatic and supportive treatment must be instituted, often requiring hospital-based observation. Treatment protocols described in official documentation include the use of activated charcoal and volume expansion with warmed intravenous fluids for circulatory collapse.

The regulatory documents emphasize that no specific antidote is known for Alimemazine. Therefore, management focuses on intensive clinical follow-up and appropriate resuscitation measures in a hospital setting to manage the documented severe systemic effects.

Therapeutic Uses of Vallergan

What Vallergan Treats: Main Uses and Benefits

Vallergan is commonly used in contexts involving certain distressing symptoms across two main areas of symptomatic management.


Intense Allergic Itching and Skin Discomfort

Vallergan is commonly used to address symptom clusters that may become intense or disruptive related to inflammatory or irritative states. It is relevant for managing symptoms that interfere with daily comfort, particularly those symptoms related to inflammatory or irritative states and episodic or fluctuating manifestations. This medication provides supportive relief when symptoms interfere with routine activities and contributes to easing the overall symptom load.

Quick Fact: Relief for Pruritus (Intense Itching)


Short-Term Restlessness and Sleep Support

Vallergan is also applied across domains where additional symptomatic support is needed, and is relevant for short-term symptom management related to increased discomfort or tension. It is often used during phases when symptoms create noticeable physiological strain and may affect the ability to rest. This supportive relief assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms by managing symptoms that interfere with routine activities.

Regulatory References

  1. Vallergan 10 mg Film-coated Tablets. - Summary of Product Characteristics

Eligibility and Restrictions for Use

Eligibility Scope

Population Group Eligibility Status
Adults & Children > 2 Years Allowed for symptomatic relief.
Infants (< 2 Years) Contraindicated (Absolute Ban).
Older Adults (Geriatric) Use requires caution; reduced dosage required.

Populations for whom use is contraindicated: Patients with known hypersensitivity to Alimemazine or other phenothiazines, severe hepatic or renal dysfunction, epilepsy, Parkinson’s disease, hypothyroidism, narrow-angle glaucoma, or prostatic hypertrophy are strictly prohibited from use.

Pregnancy and lactation eligibility status: Use during pregnancy should be avoided unless deemed essential by a physician. Breastfeeding must be suspended during treatment.

Eligibility-related restrictions: Caution is necessary for patients with certain cardiovascular diseases and those with diabetes mellitus (due to excipients in some formulations).


Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated (Absolute Ban), Avoided/Suspended (Reproductive Status), Caution (Conditional Use), Reduced Dosage (Geriatric).

Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is contraindicated in patients with severe hepatic or renal dysfunction.
  • Use is contraindicated in children less than 2 years of age.
  • Use in pregnancy should be avoided unless deemed essential by a physician.

Connection to the overall eligibility profile (2–4 sentences): The official regulatory documents define Vallergan's eligibility profile by establishing strict contraindications that prohibit use in patients with specific pre-existing comorbidities. Eligibility is further structured by setting a mandatory minimum age threshold and requiring caution or a reduced dosage for older adults and patients in physiological states requiring special consideration.

What should I know about interactions with other medicines?

Official Interaction Profile for Vallergan (Alimemazine)

Official regulatory documents establish Vallergan's interaction profile through pharmacodynamic reinforcement and other documented mechanisms, defining constraints on co-administration with various medicinal products and substances.

Pharmacodynamic Interactions and Restrictions

  • Co-administration with CNS Depressants (including opiates, hypnotics, and barbiturates) results in additive CNS depressant effects.
  • Combining Alimemazine with Tricyclic Antidepressants or MAOI's (such as Moclobemide) can lead to increased antimuscarinic effects and a heightened risk of respiratory depression.
  • The hypotensive effect of Antihypertensive Drugs may be exaggerated, a warning specifically noted for elderly or volume-depleted patients.
  • The regulatory label requires caution when combining Vallergan with QT Prolonging Drugs.

Exposure and Antagonistic Interactions

  • The absorption of Vallergan may be interfered with by Antacids, Anti-Parkinson Drugs, and Lithium.
  • Alimemazine's action is documented to oppose the effects of specific drugs, including Levodopa and Adrenaline.
  • In high doses, Vallergan may reduce the response to Hypoglycaemic Agents.
  • Changes in plasma concentration observed with Propranolol and Phenobarbital were determined to be not of clinical significance.

Substance-Specific Cautions

  • Consumption of Alcoholic Beverages is strongly advised against because the sedative effects are intensified due to an additive pharmacodynamic effect.

The profile establishes regulatory constraints, focusing on combinations that alter drug effects or plasma exposure, all strictly according to official labeling.

Mechanism of Action

Vallergan (alimemazine/trimeprazine) functions primarily as a non-selective antagonist at the histamine H1 receptor

. This interaction blocks the binding of the endogenous agonist, histamine, to the H1 receptor, a G-protein coupled receptor (GPCR) predominantly found on peripheral and central nervous system cells. By preventing histamine binding, the drug inhibits the downstream Gq-coupled signaling cascade, which normally involves the activation of phospholipase C and the subsequent increase in intracellular IP3 (inositol trisphosphate) and DAG (diacylglycerol), ultimately leading to calcium release and cellular response. The blockade of H1 receptors in peripheral tissues leads to the physiological consequence of reduced microvascular permeability and vasodilation. Furthermore, due to its lipophilicity, Vallergan crosses the blood-brain barrier, enabling central H1 receptor antagonism. The molecule also exhibits affinity for other neuroreceptors, including muscarinic cholinergic receptors and dopamine D2 receptors, where it acts as an antagonist. Central D2 receptor antagonism modulates dopaminergic neurotransmission in various brain regions. This pleiotropic antagonism on multiple neurotransmitter systems contributes to systemic central nervous system modulation.

Dosage and Administration Information

How Vallergan Is Used: Official Administration Guidelines

Vallergan, containing Alimemazine (Trimeprazine), is administered orally in the form of film-coated tablets (e.g., 10 mg strength) or as an oral solution or syrup. Its use follows a flexible, short-term, divided daily regimen.


Official Dosing and Frequency

Administration is generally structured around taking divided doses throughout the day, with the recommendation that evening dosing is preferable due to the pronounced sedative effect of the medicine. The standard daily dosage must be split into multiple administrations, not to exceed four daily doses.

Population Typical Standard Daily Regimen Single Dose Range
Adults (Pruritus) 30 to 40 mg total in divided doses. 10 mg two or three times daily
Older Adults Reduced dose of 10 mg once or twice daily.
Children (over 2 years) 2.5 mg to 5 mg three or four times daily (syrup is commonly used).

Administration Conditions and Duration

Vallergan may be taken with or without food. When using the oral solution or syrup, the dose must be accurately measured using a graduated dosing aid to ensure the correct volume is administered. Use of the medicine is typically short-term and should be stopped when the itching and redness have gone.

If a dose is missed, users are instructed to skip the missed dose and take the next dose at the scheduled time; a double dose must not be taken to make up for the missed one.

Recent Clinical Evidence

Vallergan: Recent Clinical Evidence

Vallergan, which contains the active ingredient trimeprazine tartrate (alimemazine), has been studied in clinical settings primarily for its antihistamine and sedative properties. The majority of recent clinical research, particularly involving its use in pediatrics, has focused on outcomes related to sedation and sleep disturbance.

Sedation and Sleep Studies

Studies evaluating trimeprazine for night waking in young children (e.g., 1 to 3 years old) have generally reported short-term effects. In double-blind, placebo-controlled trials, children receiving trimeprazine often showed statistically significant improvements in sleep variables, such as fewer wakings and increased night-time sleep, when compared to placebo in the short term. However, the clinical significance of these changes has been noted as less clear by reviewers, and follow-up observations frequently showed no significant difference from baseline measures.

  • Key Findings: Some trials demonstrated that the effects of trimeprazine were not consistently replicated across participants, particularly with lower doses.

Use as an Adjunct

Trimeprazine has also been investigated as an agent for premedication prior to surgical or dental procedures in children. The goal is to provide sedation and manage anxiety. One retrospective study on dental procedures indicated that younger children (3–5 years old) may be more likely to have successful sedation compared to older children (6–8 years old) using trimeprazine. Research continues to explore the role of trimeprazine, often suggesting its use as an adjunct to behavioral therapy programs rather than as a standalone pharmacological treatment for sleep disturbance.

Area of Research Primary Outcome Assessed Limitation Noted in Studies
Night Waking Reduction in frequency/duration of wakings Effects were often not sustained long-term or replicated across all doses.
Pediatric Sedation Successful cooperation during dental/medical procedures Higher doses were sometimes associated with prolonged recovery times.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE) Guidelines: Sedation for diagnostic and therapeutic procedures in children and young people

Frequently Asked Questions (FAQ)

Common questions about Vallergan (FAQ)


Q: How quickly does Vallergan typically start working?

Official product information on Vallergan's properties indicates that the active substance begins to appear in the bloodstream relatively quickly. Its peak concentration is typically measured in about one to two hours after taking a dose orally. This time frame is when the substance’s maximum concentration is generally observed.


Q: How long does the effect of Vallergan usually last?

Vallergan is known for a relatively long duration of action due to how the body processes the medicine. This long half-life contributes to the practice of taking the dose in the evening when it is used for sleep-related issues, as noted in some official prescribing documents.


Q: Can Vallergan be used during pregnancy or while breastfeeding?

Regulatory documents advise that use during pregnancy should be avoided unless it is deemed essential by a healthcare professional. Use while breastfeeding is not recommended because the active substance is known to pass into breast milk.


Q: Does Vallergan interact with herbal supplements?

Official drug labels primarily list interactions with other pharmaceutical drugs and alcohol. However, official guidance advises caution when combining Vallergan with any other substance that has a sedating or anticholinergic effect, as this combination could potentially increase sedative side effects.


Q: Can Vallergan affect the results of allergy skin tests?

As Vallergan is a first-generation antihistamine, its action blocks the effects of histamine. Regulatory guidance for this drug class suggests that this action may interfere with and potentially suppress positive results on allergy skin tests. Individuals should consult their health professional regarding the timing of the drug and any planned allergy testing.


Q: Does Vallergan cause weight gain?

While regulatory documents provide a full list of potential adverse reactions, weight gain is generally not listed among the frequently or commonly reported side effects associated with Vallergan in official product information.


Q: Why might a doctor prescribe Vallergan instead of a newer medication?

Official prescribing guidance notes that Vallergan is a highly sedating antihistamine. It may be selected specifically when a strong sedative effect is required to manage severe itching, restlessness, or sleep disruption. Newer antihistamines are often non-sedating, making them inappropriate for these particular therapeutic goals.


Q: Has Vallergan been studied in patients with liver problems?

Regulatory documents indicate that Vallergan is contraindicated (absolutely prohibited) for use in patients with severe hepatic dysfunction (severe liver disease). This restriction is in place because impaired clearance can lead to drug accumulation, which presents an increased risk of toxicity.


Q: Does Vallergan belong to the same group of medicines as Benadryl?

Vallergan is officially classified as a first-generation phenothiazine antihistamine. Medicines like Benadryl (diphenhydramine) are also classified within the first-generation antihistamine group. They share core pharmacological properties, including H1 receptor blockade and an ability to affect the central nervous system.


Q: Is there research evidence for Vallergan's use in insomnia?

Research evidence cited in regulatory contexts often focuses on Vallergan’s use for treating sleep disturbance associated with conditions like itching or anxiety. Official reviews have noted that the data for its use solely as a dedicated hypnotic drug for primary insomnia may be limited.


Q: What are the official uses of Vallergan in different countries?

Official licensed indications for Vallergan can vary slightly based on the local regulatory authority. The most common uses generally include the symptomatic treatment of pruritus (itching) and, in some regions, its use for pre-operative sedation in children.


Q: What should be done if a dose of Vallergan is missed?

Official patient information describes that if a dose is missed, individuals should skip the missed dose and take the next dose at the scheduled time. It is explicitly stated that a double dose must not be taken to make up for the dose that was missed.


Q: Are there any special dietary concerns while taking Vallergan?

Regulatory documents state that Vallergan can be taken with or without food, meaning no special restrictions are usually noted. The strongest warning regarding consumption is the strict advice against the use of alcoholic beverages, which can intensify the drug's sedative effects.


Q: Can Vallergan be crushed or split?

Vallergan is supplied as a liquid syrup and as film-coated tablets. General pharmaceutical guidance suggests that film-coated tablets are typically intended to be swallowed whole unless the tablet is scored or the official product information specifically allows crushing or splitting.


Q: Does Vallergan have potential for dependence or withdrawal effects?

Official drug safety information generally focuses on the drug's short-term use, and data on dependence is limited. Sudden stopping after chronic use of this drug class may be associated with temporary effects like activation or insomnia.


Q: Is Vallergan commonly used for coughs or colds?

The official primary indications for Vallergan focus on the relief of severe itching and associated restlessness or sedation. Official primary indications do not generally include its use for common cough or cold symptoms in its single-ingredient form.


Q: Is Vallergan available over the counter in some places?

In all countries where Vallergan is currently marketed and licensed, it is uniformly classified as a prescription-only medicine. The drug’s strong sedative and effects on the nervous system require medical supervision, preventing its sale as an over-the-counter product.


Q: Does Vallergan make allergies worse if stopped suddenly?

Official product information emphasizes that use should be short-term and does not indicate that the drug causes a rebound or worsening of the original allergy symptoms when stopped. However, the abrupt cessation of a sedating drug may sometimes lead to temporary effects like insomnia.


Q: Are there any reported interactions between Vallergan and common foods?

Regulatory documents confirm that Vallergan can be taken before or after food, and the official interaction profile does not list any specific restrictions or negative interactions between the medicine and common foods.


Q: Why are some people concerned about Vallergan and the heart rhythm?

Regulatory agencies require caution when Vallergan is combined with certain other medicines known as QT Prolonging Drugs. The risk relates to the possibility of the drug, or its interactions, potentially affecting the heart’s electrical activity, which is a key safety consideration for this drug class.


Q: How does Vallergan's sedative effect compare to other first-generation antihistamines?

Vallergan is classified by regulatory-cited pharmacologists as a highly sedating first-generation antihistamine due to its chemical structure and ability to cross the blood-brain barrier. This sets it apart from less-sedating drugs in the same class.


Q: What are the known potential interactions with psychiatric medications and Vallergan?

Official product information warns about significant interactions, including increased risk of side effects, when combining Vallergan with Tricyclic Antidepressants (TCAs) and Monoamine Oxidase Inhibitors (MAOIs), due to cumulative effects on the nervous system and anticholinergic side effects.


Q: Is there a maximum time recommended for continuous Vallergan use?

Official documents specify that the use of Vallergan is typically short-term and should be stopped once the symptoms it is treating (such as severe itching and restlessness) have been resolved. The recommended duration of treatment should be determined by a healthcare professional.


Q: What research exists regarding Vallergan and long-term cognitive effects?

Regulatory-cited reviews on Vallergan tend to focus on its short-term outcomes for sleep and sedation. Concerns regarding potential long-term cognitive effects are often noted in the context of the drug's strong effects on the central nervous system and its anticholinergic properties, which are characteristic of this older drug class.


Q: Do regulatory agencies classify Vallergan's safety differently for children versus adults?

Yes, official regulatory documents apply different safety classifications based on age. The drug is strictly contraindicated in children under 2 years due to the high risk of severe sedation. Furthermore, a reduced dosage is specifically required for older children and elderly patients compared to standard adult doses.


Q: Does Vallergan have any uses beyond its antihistamine and sedative properties?

Regulatory documents note that Vallergan, as a phenothiazine derivative, also affects muscarinic cholinergic receptors and dopamine D2 receptors. This action on multiple nerve signaling systems contributes to its diverse range of effects on the body beyond simple H1 antihistamine properties.

How should Vallergan be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documents define strict conditions for storing and disposing of Vallergan (alimemazine/trimeprazine) to maintain its stability and ensure safety.

Requirement Area Official Guidelines
Temperature Store below 25 C (syrup/elixir) or below 30 C (tablets).
Light Protection Keep the medicine in its original outer carton, protected from light.
Stability (Syrup) Discard the syrup or elixir within 1 month after first opening the bottle.
Child Safety Keep Vallergan out of the reach of children. The syrup is supplied with a child-proof cap.
Disposal Do not use expired medicine. Return all unused or expired Vallergan to a pharmacist for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vallergan found in:

A-Z Index: